Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
BMC Pulmonary Medicine|October 17, 2019
Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbationSung Woo Moon, Moo Suk Park, Young Sam Kim, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2012
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC)Se Hyun Kim, Hyo Sup Shim, Jaeho Cho, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancerSun Min Lim, Hyun Chang, Yoon Jin Cha, et al.
The Oncologist|March 30, 2016
MET Exon 14 Skipping in Non-Small Cell Lung CancerRebecca S Heist, Hyo Sup Shim, Shalini Gingipally, et al.
Experimental & Molecular Medicine|July 31, 2023
The deubiquitinase UCHL3 mediates p300-dependent chemokine signaling in alveolar type II cells to promote pulmonary fibrosisSoo Yeon Lee, Soo-Yeon Park, Seung-Hyun Lee, et al.
Lung Cancer (Amsterdam, Netherlands)|November 27, 2022
Proposal of a revised International Association for the Study of Lung Cancer grading system in pulmonary non-mucinous adenocarcinoma: The importance of the lepidic proportionByung Jo Park, Wongi Woo, Yoon Jin Cha, et al.
Therapeutic Advances in Medical Oncology|January 17, 2022
Predicting treatment outcomes using <sup>18</sup>F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapyChang Gon Kim, Sang Hyun Hwang, Kyung Hwan Kim, et al.
Cancer|July 2, 2011
Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangementHye Ryun Kim, Hyo Sup Shim, Jin-Haeng Chung, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)Sun Min Lim, Byoung Chul Cho, Sang-We Kim, et al.
Thorax|December 2, 2021
Tumour-infiltrating bystander CD8<sup>+</sup> T cells activated by IL-15 contribute to tumour control in non-small cell lung cancerGalam Leem, Minwoo Jeon, Kun Woo Kim, et al.
Pageof 14